|
|
Volumn 34, Issue 7, 2016, Pages 709-715
|
|
Public biotech in 2015 - The numbers
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BEVACIZUMAB;
DEUTETRABENAZINE;
ELBASVIR PLUS GRAZOPREVIR;
ETANERCEPT;
FILGRASTIM;
IBRUTINIB;
INFLIXIMAB;
INSULIN GLARGINE;
LEDIPASVIR PLUS SOFOSBUVIR;
LENALIDOMIDE;
OZANIMOD;
PEGFILGRASTIM;
PNEUMOCOCCUS VACCINE;
RECOMBINANT GAMMA INTERFERON;
RHEIN;
RITUXIMAB;
SEBELIPASE ALFA;
SOFOSBUVIR;
TRASTUZUMAB;
ARTICLE;
BIOTECHNOLOGY;
CAPITAL;
DRUG MARKETING;
HEALTH CARE QUALITY;
HUMAN;
INCOME;
MERGERS AND ACQUISITIONS;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REIMBURSEMENT;
DRUG INDUSTRY;
ECONOMICS;
EMPLOYMENT;
PUBLIC SECTOR;
RESEARCH;
STATISTICS AND NUMERICAL DATA;
BIOTECHNOLOGY;
DRUG INDUSTRY;
EMPLOYMENT;
INCOME;
PUBLIC SECTOR;
RESEARCH;
|
|
EID: 84978376856
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt.3630 Document Type: Article |
|
Times cited : (11)
|
|
References (0)
|